Antibacterial Drugs Market by Route Of Administration, Drug Class and Geography - Forecast and Analysis 2023-2027

Published: Oct 2023 Pages: 179 SKU: IRTNTR76198

Antibacterial Drugs Market Size 2023-2027

The  Antibacterial Drugs Market size is estimated to grow by USD 9.90 billion at a CAGR of 4.21% between 2022 and 2027. Market expansion is influenced by several factors, including the rising prevalence of bacterial infections, increasing awareness of diseases and their bacterial origins, and a globally aging population. Bacterial infections are becoming more common, necessitating effective treatments and driving the demand for related medications and therapies. Greater awareness of diseases caused by bacteria, their prevention, and treatment options is also contributing to market growth. Additionally, the global aging population is more susceptible to bacterial infections, further boosting the market for related treatments. These factors underscore the market's growth potential, indicating a need for continued development and innovation in bacterial infection treatments to meet the increasing demand.

The early diagnosis of diseases is essential to minimize the chances of happening severe damage to the body. The rising awareness of different infections, including TB, and their treatments are resulting in the growing use of antibacterial drugs for the treatment of these diseases in the primitive stages. Therefore, advanced formulations and innovative approaches enable the prevention of the spreading of disease and allow for early diagnosis. Novel mechanisms of action, combination therapies, and antibiotic development play a crucial role in this regard, highlighting the importance of innovation in healthcare. There is growing awareness among people due to several health awareness programs. For example, November 18 is celebrated as the European Antibiotic Awareness Day to increase awareness about antibiotic resistance and promote the judicious use of antibiotics. Hence, such awareness programs are positively impacting the market.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

This report provides a detailed analysis of the market by and Route Of Administration (Intravenous, Oral, and Others ), Drug Class (B-lactam, Quinolones, Macrolids, Tetracyclins, and Others ), and Geography (Asia, North America, Europe, and Rest of World (ROW)).

By Route Of Administration

Intravenous

The intravenous segment is estimated to witness significant growth during the forecast period.  This segment plays a crucial role in the treatment of several infections, critical medical conditions, and situations where rapid and precise drug delivery is important. This route comprises injecting antibiotics directly into the bloodstream through a vein, enabling immediate distribution throughout the body.

Get a glance at the market contribution of various segments View a PDF Sample

The intravenous segment was the largest segment and was valued at USD 21.39 billion in 2017. There is increasing adoption of IV antibiotics across hospitals where the patient needs intensive care and frequent monitoring or cannot tolerate oral medications. Some of the main cases where antibiotics are administered intravenously include severe infection or antibiotics cannot be taken orally. The main types of intravenous administration types include injection and PICC lines. Some of the main infections that can be treated using this segment include pneumonia, severe urinary tract infections, certain intraabdominal infections, Gram-negative bacteremia, acute exacerbations of chronic lung disease, and skin and soft tissue infections. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

By Drug Class 

B-lactam

B-Lactam antibiotics, also called B-lactams, comprise a key and widely utilized class of antibacterial drugs. These antibiotics are widely used to disrupt the synthesis of bacterial cell walls, a key component for bacterial survival and growth. Some of the main examples of B-lactam are penicillins and cephalosporins. As these antibiotics show different spectra of activity against various types of bacteria, it is widely used in treating a different range of infections. There is increasing adoption of these antibiotics as they are effective against Gram-positive bacteria. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period. 

Quinolones

Quinolone antibiotics also referred to as quinolones, comprise a key class of antibacterial drugs known for their effectiveness against a wide range of bacterial infections. Some of the main infections that can be treated using this segment include respiratory, urinary tract, skin, and gastrointestinal infections. Some of the main examples of quinolone include ciprofloxacin, levofloxacin, and moxifloxacin. Hence, such factors are expected to fuel the growth of this segment which in turn will drive the market growth during the forecast period.

By Region

For more insights about the market share of various regions View PDF Sample now!

Asia is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the antibacterial market during the forecast period. One of the main reasons which have significantly contributed to the growth of the global antibacterial drugs market is the growing demand for enhanced healthcare infrastructure in the region. Some of the Key leading markets which is contributing to the growth of this market in Asia include India and China.

Furthermore, the increase in the aging population is significantly fuelling the antibacterial market growth as the aging population has low immunity which makes them vulnerable to more diseases and infections.  For example, as per the US Census Bureau's new report on aging, Asia had more than 4.5 billion people as of 2020, which is more than half of the world's population (including China and India, which have populations of over 1 billion each). Hence, such factors are expected to drive market growth in the region during the forecast period.

Buy Now Full Report and Discover More

Key Antibacterial Drugs Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers anti-bacterial drugs such as AVYCAZ or ceftazidime and avibactam, TEFLARO or ceftaroline fosamil, DALVANCE or dalbavancin, and MONUROL.

  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Binnopharm Group LLC
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Kyorin Pharmaceutical Co. Ltd.
  • Lupin Ltd.
  • Merck KGaA
  • Novartis AG
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Melinta Therapeutics LLC
  • Shionogi and Co. Ltd

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is driven by organizations like the Pew Charitable Trust and initiatives like the Global Antibiotic Research and Development Partnership (GARDP), focusing on developing novel drug classes to combat Gram-negative ESKAPE bacteria. Progression through Phase 1, Phase 2, and Phase 3 clinical trials is crucial for promising molecules. Key players invest significantly in antibiotic development, bearing high expenses to address the challenge of drug-resistant bacteria. Efforts include screening over 50,000 compounds and accessing libraries like MTPC's to discover compounds with antibacterial activity. The market thrives on innovation, offering advanced formulations and combination therapies with novel mechanisms of action to tackle bacterial challenges and improve infectious disease management. Successful products undergo regulatory submissions and receive regulatory approval, leading to product expansion with novel formulations and combination therapies. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

One of the key factors driving the market growth is the rising aging population globally. There is an increasing prevalence of bacterial infections and diseases among the aging population. For example, as per the United Nations (UN) data, the number of persons aged 65 and above is expected to more than quadruple globally, from 761 million in 2021 to 1.6 billion in 2050. 

Moreover, the elderly population has a compromised immune system due to age-related physiological changes, chronic conditions, and often complex healthcare needs which makes them more vulnerable to bacterial infections. Thus, such kinds of vulnerability can lead to serious complications and even death. Therefore, such factors are expected to drive market growth during the forecast period.

Significant Market Trends

A key factor shaping the market growth is the application of nanotechnology in antibacterial drugs. There is an increase in infectious diseases which is the main cause of mortality in the healthcare industry. There is an increasing focus on the development of novel medications due to the emergence of microorganisms carrying multidrug resistance (MDR) rendering existing medications useless against them.

Moreover, several innovative methods are extensively utilized to inhibit antimicrobial medication resistance. Thus, there is increasing research and development on the application of nanotechnology in antibacterial drugs for effective cures against such bacterial infections. Hence, such factors are expected to drive market growth during the forecast period. 

Major Antibacterial Drugs Market Challenges

Regulatory hurdles related to developing antibacterial drugs are one of the key challenges hindering market growth. The main challenge faced by the global antibacterial market is the regulatory hurdles that come with certain complexities with regulatory approvals for the development, testing, and marketing of new antibiotics. Several stringent regulatory requirements are enforced to ensure patient safety and the efficacy of these life-saving medications.

Moreover, the development and launching of new antibiotics to market include rigorous preclinical testing, extensive clinical trials, and comprehensive data submissions to regulatory agencies. Therefore, the process itself is time-consuming and expensive. Hence, such factors are negatively impacting the market which in turn will hinder the market growth during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments

  • Route Of Administration Outlook 
    • Intravenous
    • Oral
    • Others
  • Drug Class Outlook 
    • B-lactam
    • Quinolones
    • Macrolides
    • Tetracyclines
    • Others
  • Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Brazil

Market Analyst Overview

The market is characterized by agreements such as MTPC's library access for initiatives like GARDP to meet market demand and address market concentration. Market offerings include pipeline products targeting bacteria like Staphylococci, Streptococci, Clostridium, and Listeria by inhibiting cell wall synthesis and targeting the peptidoglycan layer. While penicillin remains a significant segment, cephalosporins are also crucial, belonging to the beta-lactam group effective against Gram-negative bacteria like Pseudomonas aeruginosa and Klebsiella pneumonia.

Furthermore, the market sees a demand for bactericides fragilis and generics, with seasonal usage patterns and five generations of drugs, including cefixime for Enterobacteriaceae spp. Generic antibiotics and branded antibiotics segments coexist, with a focus on investigational pipelines and product offerings supported by robust distribution networks. Inhibitors of cell wall synthesis, including cephalosporin, penicillin, and carbapenems, are prominent, while novel drugs targeting RNA synthesis are also emerging. R&D initiatives drive product launches, with drugs like rifamycins and fidaxomycin targeting RNAP.

Market Scope

Report Coverage

Details

Page number

179

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 4.21%

Market growth 2023-2027

USD 9.90 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

3.42

Regional analysis

Asia, North America, Europe, and the Rest of World (ROW)

Performing market contribution

Asia at 42%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

 Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Basilea Pharmaceutica Ltd., Bayer AG, Binnopharm Group LLC, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Kyorin Pharmaceutical Co. Ltd., Lupin Ltd., Merck KGaA, Novartis AG, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Melinta Therapeutics LLC, and Shionogi and Co. Ltd.

Market dynamics

Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period.

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global antibacterial drugs market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global antibacterial drugs market 2017 - 2021 ($ million)
    • 4.2 Route of administration Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Route of administration Segment 2017 - 2021 ($ million)
    • 4.3 Drug class Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Drug class Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Intravenous - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Intravenous - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Intravenous - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Intravenous - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Intravenous - Year-over-year growth 2022-2027 (%)
    • 6.4 Oral - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Oral - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Oral - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Oral - Year-over-year growth 2022-2027 (%)
    • 6.5 Others - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by Route of Administration
      • Exhibit 46: Market opportunity by Route of Administration ($ million)
      • Exhibit 47: Data Table on Market opportunity by Route of Administration ($ million)

    7 Market Segmentation by Drug Class

    • 7.1 Market segments
      • Exhibit 48: Chart on Drug Class - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Drug Class - Market share 2022-2027 (%)
    • 7.2 Comparison by Drug Class
      • Exhibit 50: Chart on Comparison by Drug Class
      • Exhibit 51: Data Table on Comparison by Drug Class
    • 7.3 B-lactam - Market size and forecast 2022-2027
      • Exhibit 52: Chart on B-lactam - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on B-lactam - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on B-lactam - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on B-lactam - Year-over-year growth 2022-2027 (%)
    • 7.4 Quinolones - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Quinolones - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on Quinolones - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on Quinolones - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Quinolones - Year-over-year growth 2022-2027 (%)
    • 7.5 Macrolids - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Macrolids - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Data Table on Macrolids - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Chart on Macrolids - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Macrolids - Year-over-year growth 2022-2027 (%)
    • 7.6 Tetracyclins - Market size and forecast 2022-2027
      • Exhibit 64: Chart on Tetracyclins - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Data Table on Tetracyclins - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Chart on Tetracyclins - Year-over-year growth 2022-2027 (%)
      • Exhibit 67: Data Table on Tetracyclins - Year-over-year growth 2022-2027 (%)
    • 7.7 Others - Market size and forecast 2022-2027
      • Exhibit 68: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 70: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 71: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 7.8 Market opportunity by Drug Class
      • Exhibit 72: Market opportunity by Drug Class ($ million)
      • Exhibit 73: Data Table on Market opportunity by Drug Class ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 75: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 76: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 77: Chart on Geographic comparison
      • Exhibit 78: Data Table on Geographic comparison
    • 9.3 Asia - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.4 North America - Market size and forecast 2022-2027
      • Exhibit 83: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.5 Europe - Market size and forecast 2022-2027
      • Exhibit 87: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 95: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 China - Market size and forecast 2022-2027
      • Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 103: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 104: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 Japan - Market size and forecast 2022-2027
      • Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
      • Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%)
      • Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 111: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 112: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 113: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 114: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 115: Market opportunity by geography ($ million)
      • Exhibit 116: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 117: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 119: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 120: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 121: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 122: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 123: AbbVie Inc. - Overview
              • Exhibit 124: AbbVie Inc. - Product / Service
              • Exhibit 125: AbbVie Inc. - Key news
              • Exhibit 126: AbbVie Inc. - Key offerings
            • 12.4 Bayer AG
              • Exhibit 127: Bayer AG - Overview
              • Exhibit 128: Bayer AG - Business segments
              • Exhibit 129: Bayer AG - Key news
              • Exhibit 130: Bayer AG - Key offerings
              • Exhibit 131: Bayer AG - Segment focus
            • 12.5 Bristol Myers Squibb Co.
              • Exhibit 132: Bristol Myers Squibb Co. - Overview
              • Exhibit 133: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 134: Bristol Myers Squibb Co. - Key news
              • Exhibit 135: Bristol Myers Squibb Co. - Key offerings
            • 12.6 Cipla Ltd.
              • Exhibit 136: Cipla Ltd. - Overview
              • Exhibit 137: Cipla Ltd. - Business segments
              • Exhibit 138: Cipla Ltd. - Key news
              • Exhibit 139: Cipla Ltd. - Key offerings
              • Exhibit 140: Cipla Ltd. - Segment focus
            • 12.7 Eli Lilly and Co.
              • Exhibit 141: Eli Lilly and Co. - Overview
              • Exhibit 142: Eli Lilly and Co. - Product / Service
              • Exhibit 143: Eli Lilly and Co. - Key news
              • Exhibit 144: Eli Lilly and Co. - Key offerings
            • 12.8 F. Hoffmann La Roche Ltd.
              • Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.9 GlaxoSmithKline Plc
              • Exhibit 150: GlaxoSmithKline Plc - Overview
              • Exhibit 151: GlaxoSmithKline Plc - Business segments
              • Exhibit 152: GlaxoSmithKline Plc - Key news
              • Exhibit 153: GlaxoSmithKline Plc - Key offerings
              • Exhibit 154: GlaxoSmithKline Plc - Segment focus
            • 12.10 Kyorin Pharmaceutical Co. Ltd.
              • Exhibit 155: Kyorin Pharmaceutical Co. Ltd. - Overview
              • Exhibit 156: Kyorin Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 157: Kyorin Pharmaceutical Co. Ltd. - Key offerings
            • 12.11 Lupin Ltd.
              • Exhibit 158: Lupin Ltd. - Overview
              • Exhibit 159: Lupin Ltd. - Product / Service
              • Exhibit 160: Lupin Ltd. - Key news
              • Exhibit 161: Lupin Ltd. - Key offerings
            • 12.12 Merck KGaA
              • Exhibit 162: Merck KGaA - Overview
              • Exhibit 163: Merck KGaA - Business segments
              • Exhibit 164: Merck KGaA - Key news
              • Exhibit 165: Merck KGaA - Key offerings
              • Exhibit 166: Merck KGaA - Segment focus
            • 12.13 Novartis AG
              • Exhibit 167: Novartis AG - Overview
              • Exhibit 168: Novartis AG - Business segments
              • Exhibit 169: Novartis AG - Key offerings
              • Exhibit 170: Novartis AG - Segment focus
            • 12.14 Paratek Pharmaceuticals Inc.
              • Exhibit 171: Paratek Pharmaceuticals Inc. - Overview
              • Exhibit 172: Paratek Pharmaceuticals Inc. - Product / Service
              • Exhibit 173: Paratek Pharmaceuticals Inc. - Key offerings
            • 12.15 Pfizer Inc.
              • Exhibit 174: Pfizer Inc. - Overview
              • Exhibit 175: Pfizer Inc. - Product / Service
              • Exhibit 176: Pfizer Inc. - Key news
              • Exhibit 177: Pfizer Inc. - Key offerings
            • 12.16 Sanofi
              • Exhibit 178: Sanofi - Overview
              • Exhibit 179: Sanofi - Business segments
              • Exhibit 180: Sanofi - Key news
              • Exhibit 181: Sanofi - Key offerings
              • Exhibit 182: Sanofi - Segment focus
            • 12.17 Teva Pharmaceutical Industries Ltd.
              • Exhibit 183: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 184: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 185: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 186: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 187: Teva Pharmaceutical Industries Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 188: Inclusions checklist
                • Exhibit 189: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 190: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 191: Research methodology
                • Exhibit 192: Validation techniques employed for market sizing
                • Exhibit 193: Information sources
              • 13.5 List of abbreviations
                • Exhibit 194: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              antibacterial drugs market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis